Statera BioPharma (FRA:7CB) Long-Term Debt: €0.00 Mil (As of Sep. 2022)


FRA:7CB Statera BioPharma Inc FRA:7CB
20 GF Score
Price €2.61
View Full Analysis

What is Statera BioPharma Long-Term Debt?

Statera BioPharma FRA:7CB 20 Long-Term Debt is €0.00 Mil as of Sep. 2022. GuruFocus rates FRA:7CB with a GF Score™ of 20/100.

Statera BioPharma's Long-Term Debt for the quarter that ended in Sep. 2022 was €0.00 Mil.

Statera BioPharma's annual Long-Term Debt stayed the same from Dec. 2019 (€0.00 Mil) to Dec. 2020 (€0.00 Mil) but then increased from Dec. 2020 (€0.00 Mil) to Dec. 2021 (€9.40 Mil).

Statera BioPharma  (FRA:7CB) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Statera BioPharma Long-Term Debt Related Terms

Statera BioPharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Long-Term Debt Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Long-Term Debt
0.00 0.00 9.40

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 10.98 9.40 0.00 0.00 0.00
FRA:7CB
20GF Score
Statera BioPharma Inc FRA:7CB
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €0.00 Mil mean?
Statera BioPharma (FRA:7CB) has a Long-Term Debt of €0.00 Mil as of Sep. 2022.
Is Statera BioPharma's Long-Term Debt too high?
Statera BioPharma's current Long-Term Debt is €0.00 Mil. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's Long-Term Debt compare to NRBO and PALI?
Statera BioPharma's Long-Term Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Statera BioPharma's current Long-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (FRA:7CB) has a current Long-Term Debt of €0.00 Mil. The current Long-Term Debt is €0.00 Mil. Statera BioPharma's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Statera BioPharma (FRA:7CB), the current Long-Term Debt is €0.00 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.
20GF Score

Get the complete analysis for FRA:7CB

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.61
Price